The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

Bibliography

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
   PubMed Web of Science ®Google Scholar
• John A, Lincoln SDC. An overview of gene-epigenetic-environmental contributions to MS causation. J Neurol Sci 2009;286:54-7
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9(6):599-612
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. MSc1: environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99
   PubMed Web of Science ®Google Scholar
• Ascherio A, Munger KL. MSc: environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 2007;61:504-13
   PubMed Web of Science ®Google Scholar
• Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron;2006;52(1):61-76
   Google Scholar
• Ltd. TP: Copaxone (glatiramer acetate) solution for subcutaneous injection: US prescribing information highlights [online]. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/label/2009/020622s057lblpdf
   Google Scholar
• Ltd. TP: Copaxone - the leading multiple sclerosis therapy. Available from: http:/wwwtevapharmcom/copaxone/
   Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1503-11
   PubMed Web of Science ®Google Scholar
• Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci 2011;302(1-2):96-105
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7(10):903-14
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72(23):1976-83
   PubMed Web of Science ®Google Scholar
• O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8(10):889-97
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
   PubMed Web of Science ®Google Scholar
• Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9(4):438-46
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18(2):143-52
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
   PubMed Web of Science ®Google Scholar
• Le Page E, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17(7):867-75
   PubMed Web of Science ®Google Scholar
• Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59(6):954-5
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-303
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367(12):1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Ltd. TP: Copaxone (glatiramer acetate) solution for subcutaneous injection: US prescribing information highlights [online]. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/label/2009/020622s057lblpdf
   Google Scholar
• Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. zCopolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996;64(2):209-17
   PubMed Web of Science ®Google Scholar
• Varkony H, Weinstein V, Klinger E, et al. The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother 2009;10(4):657-68
   PubMed Web of Science ®Google Scholar
• Johnson KP. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol 2010;6(5):643-60
   PubMed Web of Science ®Google Scholar
• Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2012;12(4):371-84
   PubMed Web of Science ®Google Scholar
• Kala M, Rhodes SN, Piao WH, et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010;221(1):136-45
   PubMed Web of Science ®Google Scholar
• Ltd. TP: Copaxone 20 mg/mL, solution for injection, pre-filled syringe: UK prescribing information [online]. Available from: http://emcmedicinesorguk/medicine/17516/SPC/Copaxone+20 mg+ml%2+Solution+For+Injection%2c+Pre-Filled+Syringe/.
   Google Scholar
• Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells–specificity and promiscuity. Proc Natl Acad Sci USA 1994;91(11):4872-6
   PubMed Web of Science ®Google Scholar
• Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003;170(9):4483-8
   PubMed Web of Science ®Google Scholar
• Jung S, Siglienti I, Grauer O, et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004;148(1-2):63-73
   PubMed Web of Science ®Google Scholar
• Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129(Pt 5):1293-305
   PubMedGoogle Scholar
• Chabot S, Yong FP, Le DM, et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002;8(4):299-306
   PubMed Web of Science ®Google Scholar
• Pul R, Morbiducci F, Skuljec J, et al. Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients. PLoS One 2012;7(12):e51867
   PubMedGoogle Scholar
• Pul R, Moharregh-Khiabani D, Skuljec J, et al. Glatiramer acetate modulates TNF-alpha and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmune Pharmacol 2011;6(3):381-8
   PubMed Web of Science ®Google Scholar
• Jezewska E, Bjorkholm M, Giscombe R, et al. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease. Clin Exp Immunol 1985;61(1):96-102
   PubMed Web of Science ®Google Scholar
• Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell – friend or foe in autoimmune disease? Scand J Immunol 2002;55(5):432-41
   PubMed Web of Science ®Google Scholar
• Benczur M, Petranyl GG, Palffy G, et al. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol 1980;39(3):657-62
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 1999;96(2):634-9
   PubMed Web of Science ®Google Scholar
• Gran B, Tranquill LR, Chen M, et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000;55(11):1704-14
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Sela M, Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997;94(20):10821-6
   PubMed Web of Science ®Google Scholar
• Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12(5):543-53
   PubMed Web of Science ®Google Scholar
• Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000;105(7):967-76
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998;91(1-2):135-46
   PubMed Web of Science ®Google Scholar
• Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005;102(18):6449-54
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Stock A, et al. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 2010;225(1-2):100-11
   PubMed Web of Science ®Google Scholar
• Tennakoon DK, Mehta RS, Ortega SB, et al. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176(11):7119-29
   PubMed Web of Science ®Google Scholar
• Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115(1-2):152-60
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Brenner T, Abramsky O, et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003;9(6):592-9
   PubMed Web of Science ®Google Scholar
• Basile E, Gibbs E, Aziz T, Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006;177(1-2):161-6
   PubMed Web of Science ®Google Scholar
• Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 2011;235(1-2):9-17
   PubMed Web of Science ®Google Scholar
• Begum-Haque S, Christy M, Ochoa-Reparaz J, et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011;232(1-2):136-44
   PubMed Web of Science ®Google Scholar
• Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12(5):543-53
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Leitner O, et al. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 2000;97(21):11472-7
   PubMed Web of Science ®Google Scholar
• Aharoni R, Meshorer A, Sela M, Arnon R. Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 2002;126(1-2):58-68
   PubMed Web of Science ®Google Scholar
• Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003;100(24):14157-62
   PubMed Web of Science ®Google Scholar
• Hestvik AL, Skorstad G, Price DA, et al. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008;14(6):749-58
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000;6(6):378-81
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002;125(Pt 11):2381-91
   PubMedGoogle Scholar
• Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003;215(1-2):37-44
   PubMed Web of Science ®Google Scholar
• Aharoni R, Eilam R, Domev H, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005;102(52):19045-50
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 2007;13(3):313-31
   PubMed Web of Science ®Google Scholar
• Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006;406(3):270-5
   PubMed Web of Science ®Google Scholar
• Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005;167(1-2):215-18
   PubMed Web of Science ®Google Scholar
• Aharoni R, Sasson E, Blumenfeld-Katzir T, et al. Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate. Exp Neurol 2013;240:130-44
   PubMed Web of Science ®Google Scholar
• Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000;97(13):7446-51
   PubMed Web of Science ®Google Scholar
• Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001;98(6):3398-403
   PubMed Web of Science ®Google Scholar
• Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004;101(25):9435-40
   PubMed Web of Science ®Google Scholar
• Laurie C, Reynolds A, Coskun O, et al. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neuroimmunol 2007;183(1-2):60-8
   PubMed Web of Science ®Google Scholar
• Angelov DN, Waibel S, Guntinas-Lichius O, et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2003;100(8):4790-5
   PubMed Web of Science ®Google Scholar
• Ben-Zeev B, Aharoni R, Nissenkorn A, Arnon R. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome. Med Hypotheses 2011;76(2):190-3
   PubMed Web of Science ®Google Scholar
• Aharoni R, Yussim A, Sela M, Arnon R. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Int Immunopharmacol 2005;5(1):23-32
   PubMed Web of Science ®Google Scholar
• Aharoni R, Sonego H, Brenner O, et al. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells. Immunol Lett 2007;112(2):110-19
   PubMed Web of Science ®Google Scholar
• Research CfDEa: clinical pharmacology and biopharmaceutics review: glatiramer acetate [online]. Available from: http://wwwaccessdatafdagov/drugsatfdadocs/nda/2001/020622S015_COPAXONE_INJECTION_APpdf
   Google Scholar
• Lobel E R-KR, Amselem A, et al. Copolymer-1. Drugs Future 1996;21(2):131-4
   Google Scholar
• Ziemssen T NO, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001;24(13):979-90
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70(12):1545-77
   PubMed Web of Science ®Google Scholar
• Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report. J Neurol Sci 1977;31(3):433-8
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller AI, Teitelbaum D, et al. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 1982;11(3):317-19
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller AI, Slagle S, et al. Clinical trials of copolymer I in multiple sclerosis. Ann N Y Acad Sci 1984;436:366-72
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317(7):408-14
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]. Neurology 2001;57(12 Suppl 5):S46-53
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis. Neurology 2002;58(Suppl 3):A458
   Google Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12(3):309-20
   PubMed Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16(3):342-50
   PubMed Web of Science ®Google Scholar
• Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000;54(4):813-17
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49(3):290-7
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Comi G, Filippi M, et al. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 2002;59(8):1284-6
   PubMed Web of Science ®Google Scholar
• Rovaris M, Comi G, Rocca MA, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 2007;13(4):502-8
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73(3):327-40
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18(1):69-77
   PubMed Web of Science ®Google Scholar
• Zwibel H, Pardo G, Smith S, et al. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol 2011;258(3):402-11
   PubMed Web of Science ®Google Scholar
• Kovalchin J, Krieger J, Collins K, et al. Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301; a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers. J Clin Pharmacol 2011;51(5):649-60
   PubMed Web of Science ®Google Scholar
• Kovalchin J, Krieger J, Genova M, et al. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. J Neuroimmunol 2010;225(1-2):153-63
   PubMed Web of Science ®Google Scholar
• Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? J Neurol 2008;255(8):1250-3
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010;75(20):1794-802
   PubMed Web of Science ®Google Scholar